Y
Yoshiya Tanaka
Researcher at University of Occupational and Environmental Health Japan
Publications - 11
Citations - 2144
Yoshiya Tanaka is an academic researcher from University of Occupational and Environmental Health Japan. The author has contributed to research in topics: Rheumatoid arthritis & Tocilizumab. The author has an hindex of 10, co-authored 11 publications receiving 1142 citations.
Papers
More filters
Journal ArticleDOI
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
Martin Aringer,Karen H. Costenbader,David I. Daikh,Ralph Brinks,Marta Mosca,Rosalind Ramsey-Goldman,Josef S Smolen,David Wofsy,Dimitrios T. Boumpas,Diane L. Kamen,David Jayne,Ricard Cervera,Nathalie Costedoat-Chalumeau,Betty Diamond,Dafna D. Gladman,Bevra H. Hahn,Falk Hiepe,Søren Jacobsen,Dinesh Khanna,Kirsten Lerstrøm,Elena Massarotti,Joseph M. McCune,Guillermo Ruiz-Irastorza,Jorge Sanchez-Guerrero,Matthias Schneider,Murray B. Urowitz,George Bertsias,Bimba F. Hoyer,Nicolai Leuchten,Chiara Tani,Sara K. Tedeschi,Zahi Touma,Gabriela Schmajuk,Branimir Anić,Florence Assan,Tak Mao Chan,Ann E. Clarke,Mary K. Crow,László Czirják,Andrea Doria,Winfried Graninger,Bernadett Halda-Kiss,Sarfaraz Hasni,Peter M. Izmirly,Michelle Jung,Gábor Kumánovics,Xavier Mariette,Ivan Padjen,José M. Pego-Reigosa,Juanita Romero-Diaz,Íñigo Rúa-Figueroa Fernández,Raphaèle Seror,Georg Stummvoll,Yoshiya Tanaka,Maria G Tektonidou,Carlos Vasconcelos,Edward M Vital,Daniel J. Wallace,Sule Yavuz,Pier Luigi Meroni,Marvin J. Fritzler,Ray Naden,Thomas Dörner,Sindhu R. Johnson +63 more
TL;DR: To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism and the American College of Rheumatology (ACR).
Journal ArticleDOI
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Martin Aringer,Karen H. Costenbader,David I. Daikh,Ralph Brinks,Marta Mosca,Rosalind Ramsey-Goldman,Josef S Smolen,David Wofsy,Dimitrios T. Boumpas,Dimitrios T. Boumpas,Diane L. Kamen,David Jayne,Ricard Cervera,Nathalie Costedoat-Chalumeau,Betty Diamond,Dafna D. Gladman,Bevra H. Hahn,Falk Hiepe,Søren Jacobsen,Dinesh Khanna,Kirsten Lerstrøm,Elena Massarotti,Joseph M. McCune,Guillermo Ruiz-Irastorza,Jorge Sanchez-Guerrero,Matthias Schneider,Murray B. Urowitz,George Bertsias,Bimba F. Hoyer,Nicolai Leuchten,Chiara Tani,Sara K. Tedeschi,Zahi Touma,Gabriela Schmajuk,Branimir Anić,Florence Assan,Tak Mao Chan,Ann E. Clarke,Mary K. Crow,László Czirják,Andrea Doria,Winfried Graninger,Bernadett Halda-Kiss,Sarfaraz Hasni,Peter M. Izmirly,Michelle Jung,Gábor Kumánovics,Xavier Mariette,Ivan Padjen,José M. Pego-Reigosa,Juanita Romero-Diaz,Íñigo Rúa-Figueroa Fernández,Raphaèle Seror,Georg Stummvoll,Yoshiya Tanaka,Maria G Tektonidou,Carlos Vasconcelos,Edward M Vital,Edward M Vital,Daniel J. Wallace,Sule Yavuz,Pier Luigi Meroni,Marvin J. Fritzler,Ray Naden,Thomas Dörner,Sindhu R. Johnson,Sindhu R. Johnson +66 more
TL;DR: These new classification criteria for systemic lupus erythematosus have excellent sensitivity and specificity, and were developed using rigorous methodology with multidisciplinary and international input.
Journal ArticleDOI
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
Yoshiya Tanaka,Shintaro Hirata,Satoshi Kubo,Shunsuke Fukuyo,Kentaro Hanami,Norifumi Sawamukai,Kazuhisa Nakano,Shingo Nakayamada,Kunihiro Yamaoka,Fusae Sawamura,Kazuyoshi Saito +10 more
TL;DR: The possibility of remaining ADA-free for 1 year was demonstrated in established patients with RA with outcomes that ADA can be discontinued without flaring in 79% patients with deep remission, with similar rates in the ADA continuation group, and showed no functional or structural damage in patients with DAS28-ESR <3.2.
Journal ArticleDOI
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
Tsutomu Takeuchi,Yoshiya Tanaka,Naoki Ishiguro,Hisashi Yamanaka,Toshiyuki Yoneda,Takeshi Ohira,Naoki Okubo,Harry K. Genant,Désirée van der Heijde +8 more
TL;DR: Addition of denosumab to methotrexate has potential as a new therapeutic option for patients with RA with risk factors of joint destruction and no obvious evidence of an effect on joint space narrowing was observed.
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
Tsutomu Takeuchi,Yoshiya Tanaka,Naoki Ishiguro,Hisashi Yamanaka,Toshiyuki Yoneda,Takeshi Ohira,Naoki Okubo,Harry K. Genant,Désirée van der Heijde +8 more
TL;DR: In this paper, the authors evaluated the efficacy and safety of three different regimens of denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor kappa B (RANK) ligand, for Japanese patients with rheumatoid arthritis.